Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q2 2025 Earnings Presentation
21 slides from Q-linea Ab's earnings presentation, Jul 10, 2025
Slide 1: 2025 Q2 Report
Sustainable healthcare for a new generation 2025 Q2 Report July 10th, 2025
Slide 2: Disclaimer
Disclaimer THIS PERESNTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. T
Slide 3: Topics for today
Commercial progress update Customer engagement and feedback Topics for Progress against 2025 ambition today Financial update Respond to your questions
Slide 4: Key messages for today
Key messages for today Q2 placements on plan with five additional ASTars contracted and 1 growing pipeline of active commercial evaluations H2 2025 commercial outlook strong based on current active 2 pipeline and growing visibility on contract cycles 3 Clinical evidence and customer engagement reinf
Slide 5: Q-linea revolutionising AST | Flagship ASTar platform designed to save lives
Q-linea revolutionising AST | Flagship ASTar platform designed to save lives Fully-automated, random 1st access platform Minutes hands-on time ~2 simple interface, load-and-go system Comprehensive menu High reproducibility Hours turn-around time ~6 High throughput with 12 samples in parallel s
Slide 6: Sales development | Continued progress on installed base growth
Sales development | Continued progress on installed base growth ASTar units contracted for routine clinical use at end-of-period Five additional ASTars contracted 30 – 40 Italy in the lead with 8 systems active or contracted for deployment 14 First US system going live in July; stocking and 9
Slide 7: Market is following the typical innovation adoption curve
Anticipated timing for Global market adoption TODAY END-2026 END-2027 Market is following the ITALY YE 2025 typical ITALY innovation GCC US/EU adoption curve 2 – 3% 10 – 15% 35% 30 – 35% 15% Innovators Early Adopters Minimum viable product Winning product / tech. Exploration & research Diffe
Slide 8: Taking lead in USA | ASM Microbe 2025 conference was a success!
Taking lead in USA | ASM Microbe 2025 conference was a success! Rapid AST a major topic for clinical seminars 15+ industry-sponsored posters on rapid AST, Q-linea with seven Increasing awareness of limitations of existing AST (SoC) systems, i.e., EA/CA results Urgent plea for labs to update br
Slide 9: EMEA H2 outlook strong | Customer word-of-mouth reinforcing ASTar proposition
EMEA H2 outlook strong | Customer word-of-mouth reinforcing ASTar prop Italy with sustained momentum and outlook Tuscany ESTAR decision expected July 2025 (9 labs) Good visibility on multiple lab decisions for H2 2025 ASTar with high win rate, esp. in larger labs Distribution markets expected
Slide 10: Customer experience | Published data reinforcing ASTar impact & usability
Customer experience | Published data reinforcing ASTar impact & usability Seven publications presented at ASM 2025 reinforce Q-linea leadership Publishing institution Institution description Publication title Implication of findings 50+ hospital IDN and leading Advancing Antimicrobial Therapy: Evalu
Slide 11: Market evolution | Commercial activity concentrating to a few players
Market evolution | Commercial activity concentrating to a few players Global rAST Announced US placements in 2025 Leaders Q-linea leading both sides of Atlantic BioMérieux leveraging strong established customer base (cross-selling) Regional rAST Regional commercial efforts Specialists Focu
Slide 12: Market evolution | Customers increasingly able to discriminate available rAST solutions
Market evolution | Customers increasingly able to discriminate available rAST solutions Head-to-head evaluations, clinical studies, white papers, tender decisions, in-lab experience aligning on key criteria for rAST Global rAST Leaders Regional rAST Specialists Limited activity Gram-negative rAST in
Slide 13: Recap | Building a $600 – 900 million market segment for blood stream infection testing
Recap | Building a $600 – 900 million market segment for blood stream infection testing Clinical value Current standard of care Emerging new standard of care of information Colony-based AST Positive Blood Culture AST Whole Blood AST 5 – 7m blood infection tests Clinically- 5 – 10m critical non-b
Slide 14: Update | Status against our ambition for the year
Update | Status against our ambition for the year Commercial Progress Clinical Progress Financial Progress Increasing pace of contracted units Mounting clinical evidence Funding 2024 ≤ Q1 ≤ Q2 ≤ Q3 … LIFETIMES study LPI (last Rights issue complete (Jan) First multi-site contract signed (
Slide 15: Board of Directors | Welcome Johan Bygge and Sebastian Backlund to the team!
Board of Directors | Welcome Johan Bygge and Sebastian Backlund to the team! Johan Bygge Mario Gualano Erika Kjellberg Eriksson Karin Fischer Sebastian Backlund Jonas Jarvius Chairman of the Board Deputy Chairman of the Board Director of the Board Director of the Board Director of the Board Director
Slide 16: Financial highlights | Second quarter and H1 2025
Financial highlights | Second quarter and H1 2025 REVENUES Low Net sales in the quarter (SEK 1.1 million), explained by Q1 sold instruments undergoing installation; expect recurring revenues from Q3 on newly-installed base Strong start in July with consumables orders, in line with expectations Net s
Slide 17: OPEX development | 2023 – 2025Q2
OPEX development | 2023 – 2025Q2 Personnel expenses + Other external costs Cost program implemented Q2 2024 delivers as planned 25 000 approx. SEK 50 million savings annually 20 000 A clear shift with less personnel and expenses directly 15 000 involved in R&D, and an increase of sales, sales su
Slide 18: Funding | Share issue with support/use of warrants
Funding | Share issue with support/use of warrants SEK million Subscription (%) Share price (öre) 10 20 30 40 50 60 70 80 90 100 15 22 44 66 89 111 133 155 177 199 222 14 21 41 62 83 103 124 145 165 186 207 13 19 38 58 77 96 115 134 154 173 192 Subscription price: 3 öre 12 18 35 53 71 89 106 124 1
Slide 19: Events to come | Reverse share split in July
Events to come | Reverse share split in July July 8: PR announcing the timetable for the reverse share split AGM decision, 1:1000, i.e., 1000 shares combined into 1 share Number of shares will decrease from 6,436,873,000 to 6,436,873 Company's share will change its ISIN code as of 14 July 2025. Th
Slide 20: Future financing
Future financing Secured financing: Cash at hand 30 of June 2025: SEK 82,7 million (inlcluding all proceeds from recent capital raise) Additional sources of financing Non-dilutive financing Grants, actively seeking, EU, other Hybrid financing Convertible debenture type, actively seeking, EU Loan
Slide 21: Thank you!
Thank Questions? you!